Antidepressant candidate zuranolone modest efficacy offsets benefits
A mild-to-moderate dosing of a highly effective drug has been approved for use in the US. But what does this mean for the British drugs market, asks Tom de Castella, chief medical officer at the Royal College of Surgeons.
Source: clinicaltrialsarena.comPublished on 2021-09-30
Related news
- Arresting the Recruitment Crisis
- United States Postal Regulatory Commission Hiring CDO
- Railway must respond to wider societal changes
- Arresting the Recruitment Crisis
- Optus : data is gold
- IMS alumna Emmy Chirchir from Kenya : ″ It ′ s the chance of a lifetime !″ | Alumni | DW
- Kenya : Measures to tackle Covid - 19 pandemic must not violate human rights
- TetraScience Partners with EPAM to Help Customers Scale Improved Scientific Data Outcomes